MELAS, a common mitochondrial disease associated with a m!3243A>G mutation in the tRNALeu(UUR) gene of the mitochondrial DNA, is characterized by strokes, lactic acidosis, cerebral infarction and edema. The pathogenesis of strokes and edema in MELAS is not understood. Without a proper understanding of the pathophysiology, it has not been possible to devise rational therapies for this devastating disease. Our hypothesis is that mitochondrial dysfunction in the cortical blood vessels causes a breakdown of the blood-brain barrier (BBB) leading to strokes and associated edema. We have successfully constructed a working in vitro model of a normal and MELAS BBB. We propose to study the function of the BBB in MELAS in this model. Specifically, we will analyze tight junction proteins that regulate BBB permeability, water channels, and lactate transporters and correlate our results with respiratory chain function. These in vitro studies at the cellular level will be extended to MELAS brain sections to compare and confirm our findings at the tissue level. Therapeutic management of MELAS is anecdotal and generally ineffective. Our in vitro model is a dynamic system that can be manipulated to test various BBB protective drugs, which can restore barrier function and thus can be useful therapeutic agents for strokes, lactic acidosis, and associated edema. We will use this model to test the effect of steroids in regulating water channels and of glycerphosphoinositol and interferon-b-1a in modulating the inflammatory process after strokes. First, these studies will provide insight into the physiology of the BBB. Secondly, they will reveal changes in vascular permeability in MELAS due to mitochondrial dysfunction and energy shortage. Third, the culture model will allow us to evaluate the sequence of events leading to the increase in permeability. Finally, the in vitro model provides a flexible system to test the therapeutic value of drugs to be used this devastating illness.
This proposal is a follow-up to the funded proposal ending 11-30-09, during which the in vitro BBB system was developed and characterized. It is very relevant to this Program project application, whose emphasis is on therapeutic approaches to mitochondrial diseases, especially MELAS. The results of this project may be directly translated from bench to bedside.
|Barca, Emanuele; Ganetzky, Rebecca D; Potluri, Prasanth et al. (2018) USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. Hum Mol Genet 27:3305-3312|
|Pera, Marta; Larrea, Delfina; Guardia-Laguarta, Cristina et al. (2017) Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J 36:3356-3371|
|Fryer, Robert H; Bain, Jennifer M; De Vivo, Darryl C (2016) Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS): A Case Report and Critical Reappraisal of Treatment Options. Pediatr Neurol 56:59-61|
|Varma, Hemant; Faust, Phyllis L; Iglesias, Alejandro D et al. (2016) Whole exome sequencing identifies a homozygous POLG2 missense variant in an infant with fulminant hepatic failure and mitochondrial DNA depletion. Eur J Med Genet 59:540-5|
|Piekutowska-Abramczuk, Dorota; Kocy?a-Karczmarewicz, Beata; Ma?kowska, Maja et al. (2016) No Evidence for Association of SCO2 Heterozygosity with High-Grade Myopia or Other Diseases with Possible Mitochondrial Dysfunction. JIMD Rep 27:63-8|
|Cloonan, Suzanne M; Glass, Kimberly; Laucho-Contreras, Maria E et al. (2016) Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med 22:163-74|
|Engelstad, Kristin; Sklerov, Miriam; Kriger, Joshua et al. (2016) Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy. Hum Reprod 31:1058-65|
|Ripolone, Michela; Ronchi, Dario; Violano, Raffaella et al. (2015) Impaired Muscle Mitochondrial Biogenesis and Myogenesis in Spinal Muscular Atrophy. JAMA Neurol 72:666-75|
|Levy, Rebecca J; Ríos, Purificación Gutierrez; Akman, Hasan O et al. (2014) Long survival in patients with leigh syndrome and the m.10191T>C mutation in MT-ND3 : a case report and review of the literature. J Child Neurol 29:NP105-10|
|Garone, Caterina; Garcia-Diaz, Beatriz; Emmanuele, Valentina et al. (2014) Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med 6:1016-27|
Showing the most recent 10 out of 241 publications